Answers are grounded in this paper and cite their sources.
Highlights• The chlorite-based drug leads to sustainable reduction of HbA1c values from high to low risk in over 80% of the patients and also reduces the amounts of RBC-derived AGEs.• This HbA1c-and AGE-reducing effect results from a drug-mediated redox-active clearance of highly glycated RBCs and the restoration of RBC homeostasis in blood.• The specific effect of the drug on highly glycated RBCs, without direct blood sugar-lowering, is reflected by reduction of HbA1c/ FBS values into "non-diabetic" ranges.• The removal of highly glycated RBCs and the detoxification of hemolytic products leads to termination of endothelial injury and to resolution of diabetic vasculopathy and vasculitis.• In DFU patients, the therapeutic effect of the drug on diabetic vasculopathies translated to improved and sustainable wound healing and osteomyelitis resolution.
No takes yet. Share an insight, caveat, or question.
Mohd Yazid Bajuri (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: